Adam Simpson

Adam joined the Frazier Life Sciences team as a Venture Partner in 2024. Adam has broad emerging company and operational experience with a particular focus on team building, advancing novel technologies through clinical proof of concept and leading significant fundraising, partnering and acquisition transactions.

Adam is a Venture Partner at Frazier Life Sciences, where he is focused on company creation opportunities.  Adam currently serves as the Executive Board Chair at Callio Therapeutics, a company developing multi-payload antibody-drug conjugates.

Prior to Frazier, Adam served as co-founder, Chief Executive Officer and Board member at Icosavax (Nasdaq: ICVX), a company leveraging its virus-like particle platform to develop vaccines for respiratory diseases.  He built a team that brought multiple product candidates into the clinic, including Icosavax’s RSV/hMPV combination vaccine, and led the company through its IPO and subsequent acquisition by AstraZeneca.  Prior to Icosavax, Adam served as the Chief Executive Officer and Board member at PvP Biologics, a company developing an oral enzyme to treat celiac disease.  Adam led the company from founding through its acquisition by Takeda.  Previously, Adam served as co-founder and Chief Business Officer of Meritage Pharma from inception until its sale to Shire, leading to the first FDA-approved oral product to treat eosinophilic esophagitis.

Adam has been a co-founder, executive and/or board member of eight additional life sciences companies (across therapeutics, genomics & diagnostics) that have either been acquired or gone public. Adam began his career as an attorney at Latham & Watkins LLP, focusing on life sciences transactions.

Adam holds a B.S. in biochemistry from the University of California, San Diego and a J.D. from the University of Minnesota Law School.